Patient compliance with radiation therapy schedules

A new study by Ohri et al. (with additional information in The ASCO Post) found that for certain cancers, there was a 22 percent non-compliance rate at the Montefiore/Albert Einstein Cancer Center in New York. Non-compliant patients extended their total treatment time by about a week. … READ MORE …

Gas chromatographic diagnosis of prostate cancer (maybe)

Most of our readers have probably all been aware for some time that trained dogs are able to “diagnose” prostate cancer — with a high degree of accuracy — by smelling the urine of men who do and don’t have the disease. The same is true for some other cancers too — notably bladder cancer. … READ MORE …

Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium. … READ MORE …

One patient’s journey to active surveillance

A personal story on the MedPage Today web site this week tells a tale of how one 63-year-old professional journalist trod his own journey to management of his low-risk prostate cancer on active surveillance back in 2010. It may be instructive for many other patients newly diagnosed with low- and very low-risk prostate cancer.

CureTalk program on imaging and genomics with Dr. David Lee

Yesterday evening we held a CureTalk program on the roles of new imaging and genomic/genetic tests in the diagnosis, work-up, and prognosis of prostate cancer with Dr. David Lee of the University of Pennsylvania. … READ MORE …

Nymox claims “success” in Phase II trial of NX-1207 in low-risk prostate cancer

According to a media release issued today by Nymox Pharmaceutical Corp., their investigational drug NX-1207 (now properly known by the generic name fexapotide triflutate) successfully met the designated endpoints for a Phase II clinical trial of this drug in treatment of men with low-grade, localized prostate cancer. … READ MORE …

What else was in the news today?

Today’s news contained items that run the spectrum from the clinical value of tomatoes and lycopene via the cardiovascular side effects of LHRH agonists and antagonists to the question of whether proton beam radiation therapy is really cost-effective. So here are the “news shorts” for the day: … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,369 other followers